Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25900797 | 0.80 | LMNA (0.33) | MAPK1KMT2AYEATS4LMNATSHR | |
| SCHEMBL47581 | 0.80 | MAPK1 (0.45) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL21775973 | 0.74 | MAPK1 (0.38) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL21105449 | 0.74 | DAO (0.45) | — | |
| SCHEMBL21720118 | 0.73 | ALDH1A1 (0.31) | — | |
| SCHEMBL12737778 | 0.72 | MAPK1 (0.41) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL25963953 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL14379745 | 0.70 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL21841894 | 0.70 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A | |
| SCHEMBL498360 | 0.70 | MAPK1 (0.39) | MAPK1KMT2AYEATS4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016086134-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| WO-2016086169-A1 | BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-9012656-B2 | Oligothiophene derivate as molecular probes | CELLUMINOVA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-20120315646-A1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | CELLUMINOVA AB (SE) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315646-A1 | OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES | NMT1, DNTT, NOTCH4 | MAPK1 4366/4885KMT2A 1291/4885YEATS4 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.